Original reportsAssessment of pain quality in chronic neuropathic and nociceptive pain clinical trials with the Neuropathic Pain Scale
Key words
Cited by (0)
Supported by a grant from Endo Pharmaceuticals, Inc to the University of Rochester Office of Professional Education. M.P.J. has received research support or consulting fees in the past year from AstraZeneca, Endo Pharmaceuticals, Forest Pharmaceuticals, Pfizer, and Purdue Pharma. R.H.D. has received research support, consulting fees, or speakers bureau honoraria in the past year from Allergan, Alpharma, AstraZeneca, Bristol Myers-Squibb, Eli Lilly & Co, Endo Pharmaceuticals, EpiCept Corporation, GlaxoSmithKline, Johnson & Johnson, Merck KGaA, NeurogesX, Novartis Pharmaceuticals, Pfizer, Purdue Pharma, Reliant Pharmaceuticals, and UCB Pharma. A.R.G., N.O., and B.S.G. hold stock option in Endo Pharmaceuticals. Permission to use the Neuropathic Pain Scale can be obtained from the MAPI Research Institute (e-mail address: http://www.mapi-trust.org; B.S.G. and M.P.J. receive a portion of user fees for the NPS or PQAS charged by MAPI to industry (use by academic researchers is free).